Research location
Burnsville
Minnesota, United States
Advertisement
Research activity in Burnsville
Minnesota, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 227 trials and 267 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Burnsville
227 linked trials · page 1 of 5Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL TrialNCT07200830 · 2026-03-31 · 1 site observation
RECRUITING
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07222566 · 2026-01-06 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965 · 2025-08-05 · 1 site observation
RECRUITING
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.NCT06758401 · 2025-07-23 · 1 site observation
RECRUITING
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsNCT06418204 · 2025-01-30 · 1 site observation
RECRUITING
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the BodyNCT06470243 · 2024-11-27 · 1 site observation
RECRUITING
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialNCT06096844 · 2024-07-19 · 1 site observation
RECRUITING
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerNCT06095505 · 2024-02-08 · 1 site observation
RECRUITING
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer CachexiaNCT06073431 · 2023-12-04 · 1 site observation
RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 1 site observation
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation
RECRUITING
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069 · 2022-08-18 · 2 site observations
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)NCT04852887 · 2021-06-23 · 2 site observations
RECRUITING
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 2 site observations
RECRUITING
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 1 site observation
RECRUITING
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingNCT04423211 · 2020-10-08 · 1 site observation
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 2 site observations
RECRUITING
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · 2019-05-13 · 2 site observations
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 2 site observations
RECRUITING
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerNCT03723928 · 2018-09-17 · 2 site observations
RECRUITING
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeNCT03191149 · 2018-04-25 · 2 site observations
RECRUITING
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityNCT03418961 · 2017-11-01 · 1 site observation
RECRUITING
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerNCT06632327 · 2024-12-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC PatientsNCT06538038 · 2024-09-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Mobile Health for Adherence in Breast Cancer PatientsNCT06112613 · 2024-04-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE TrialNCT06216574 · 2024-03-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsNCT05896189 · 2024-02-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379 · 2023-11-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2NCT06003231 · 2023-11-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT TrialNCT05710328 · 2023-05-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN StudyNCT05568472 · 2023-03-29 · 2 site observations
ACTIVE_NOT_RECRUITING
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)NCT05241860 · 2022-11-21 · 2 site observations
ACTIVE_NOT_RECRUITING
Investigating the Use of Genetics to Guide Pharmacologic Therapy for HypertensionNCT02988245 · 2022-06-01 · 1 site observation
UNKNOWN
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate CancerNCT05204927 · 2022-02-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate CancerNCT04600336 · 2021-10-28 · 2 site observations
COMPLETED
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close MonitoringNCT04597359 · 2021-10-05 · 2 site observations
ACTIVE_NOT_RECRUITING
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)NCT05026866 · 2021-08-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking AbilityNCT04804644 · 2021-06-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT04625647 · 2021-04-16 · 2 site observations
ACTIVE_NOT_RECRUITING
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 2 site observations
ACTIVE_NOT_RECRUITING
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal TherapyNCT04379570 · 2021-02-15 · 2 site observations
ACTIVE_NOT_RECRUITING
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsNCT04609566 · 2021-01-26 · 1 site observation
COMPLETED
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung CancerNCT04533451 · 2020-11-16 · 2 site observations
ACTIVE_NOT_RECRUITING
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE StudyNCT04316117 · 2020-09-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive BiomarkerNCT04334941 · 2020-07-20 · 2 site observations
ACTIVE_NOT_RECRUITING
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerNCT04310007 · 2020-07-13 · 2 site observations
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.